Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Nuvation Bio (NUVB) EPS (Weighted Average and Diluted) (2023 - 2025)

Nuvation Bio (NUVB) has disclosed EPS (Weighted Average and Diluted) for 3 consecutive years, with -$0.11 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 99.94% to -$0.11 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.6, a 71.56% increase, with the full-year FY2025 number at -$0.6, up 71.56% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.11 for Q4 2025 at Nuvation Bio, up from -$0.16 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.07 in Q4 2023 to a low of -$183.97 in Q4 2024.
  • A 3-year average of -$15.59 and a median of -$0.13 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 262709.05% in 2024, then surged 99.94% in 2025.
  • Nuvation Bio's EPS (Weighted Average and Diluted) stood at -$0.07 in 2023, then tumbled by 262709.05% to -$183.97 in 2024, then soared by 99.94% to -$0.11 in 2025.
  • Per Business Quant, the three most recent readings for NUVB's EPS (Weighted Average and Diluted) are -$0.11 (Q4 2025), -$0.16 (Q3 2025), and -$0.17 (Q2 2025).